SCHEMBL4679142

SCHEMBL4679142

O=C(C=C(O)c1nn[nH]n1)c1nc(Cc2cccc(F)c2)cs1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 2/20 0.38
FFAR2 O15552 2/20 0.38
KDM4E B2RXH2 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
PIN1 Q13526 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.35
CES1 P23141 1/20 0.34
NCEH1 Q6PIU2 1/20 0.34
CACNA1G O43497 1/20 0.33
CACNA1H O95180 1/20 0.33
CACNA1I Q9P0X4 1/20 0.33
FFAR1 O14842 1/20 0.33
MPO P05164 1/20 0.32
PTGER1 P34995 1/20 0.32
BRD4 O60885 1/20 0.32
PRKACA P17612 1/20 0.32
ROCK1 Q13464 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4671624 0.89 CES1 (0.40) HDAC1HDAC6CES1NCEH1PTGER1
SCHEMBL4675553 0.88 LMNA (0.36) KDM4EHDAC1HDAC6PIN1CES1
SCHEMBL4678617 0.85 HCAR2 (0.38) HCAR2KDM4ESMN1; SMN2HDAC1HDAC6
SCHEMBL4677726 0.83 CES1 (0.32) CES1NCEH1
SCHEMBL4676190 0.83 RAB9A (0.41) HCAR2FFAR2SMN1; SMN2HDAC1HDAC6
SCHEMBL4677639 0.82 HCAR2 (0.39) HCAR2FFAR2PIN1PTGDR2CES1
SCHEMBL4673597 0.82 LMNA (0.35) KDM4ESMN1; SMN2HDAC1HDAC6PTGDR2
SCHEMBL4674999 0.82 AOC3 (0.32) HDAC1HDAC6CES1NCEH1
SCHEMBL4679320 0.82 AOC3 (0.32) KDM4ESMN1; SMN2CES1NCEH1CACNA1G
SCHEMBL4672517 0.82 HCAR2 (0.39) HCAR2FFAR2PIN1PTGDR2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 HCAR2 276/4885FFAR2 2618/4885KDM4E 947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.